Tumor Treating Fields Therapy Plus Standard Systemic Therapy vs Standard Systemic Therapy Alone for Metastatic NSCLC After Progression on or After Platinum-Based Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Lancet Oncol 2023 Sep 01;24(9)1002-1017, T Leal, R Kotecha, R Ramlau, L Zhang, J Milanowski, M Cobo, J Roubec, L Petruzelka, L Havel, S Kalmadi, J Ward, Z Andric, T Berghmans, DE Gerber, G Kloecker, R Panikkar, J Aerts, A Delmonte, M Pless, R Greil, C Rolfo, W Akerley, M Eaton, M Iqbal, C LangerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.